Evidence map›Paper›PMID 40839572›Full record

ArticlePLoS pathogens2025

Multivalent mpox protein nanoparticle vaccines confer cross-protection against orthopoxvirus infection.

Lijun Zhang, Chuanyu Liu, Chenxi Yang, Xueqi Xiao, Senyu Xu, Shengfeng Wan, Kun Xu, Yan Li, Lianpan Dai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lijun ZhangLaboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Chuanyu LiuLaboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Chenxi YangLaboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Xueqi XiaoLaboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Senyu XuMedical School, University of Chinese Academy of Sciences, Beijing, China.
Shengfeng WanLaboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Kun XuResearch Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.
Yan LiLaboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Lianpan DaiLaboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.ORCID 0000-0001-8352-1327

Funding

Bill & Melinda Gates FoundationChinese Academy of SciencesNational Key R&D program of China
6 · The paper itself

Abstract

The outbreak of mpox since 2022 has driven the development of mpox virus (MPXV)-specific, subunit-based, next-generation vaccines, instead of the currently used live-attenuated vaccinia virus (VACV) vaccines. Here, we describe a self-assembling protein nanoparticle against MPXV using lumazine synthase to present viral surface proteins. Multivalent nanoparticles elicited broader and stronger immune responses against MPXV and provided superior heterologous protection in rodent models against lethal VACV challenges compared to monovalent formulations. The three antigens with the best protective efficacy (intracellular mature virus antigens M1 and E8, and extracellular enveloped virus antigen B6) were further combined as the trivalent cocktail or mosaic nanoparticle. The trivalent nanoparticles elicited higher humoral responses compared to the modified vaccinia virus Ankara, and were protective against lethal VACV challenge in mice, with the protection correlation revealed. These findings highlight the potential of multivalent nanoparticle as vaccines against MPXV and other orthopoxviruses.

Indexed as

Cross ProtectionNanoparticlesOrthopoxvirusPoxviridae InfectionsSmallpox VaccineAnimalsAntibodies, ViralAntigens, ViralFemaleMiceMice, Inbred BALB CMpox, MonkeypoxNanovaccinesVaccinia virusAntibodies, ViralAntigens, ViralNanovaccinesSmallpox Vaccine

Identifiers

PMID40839572
PMCPMC12370032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.